Category Research

Neuroscience

Unlearn and Trace Neuroscience Collaborate to Enhance ALS Clinical Trials

Unlearn and Trace Neuroscience Collaborate to Enhance ALS Clinical Trials Unlearn®, a leader in AI-powered solutions for clinical trials, has announced a strategic collaboration with Trace Neuroscience, a biotechnology company specializing in genomic therapies for neurodegenerative diseases. This partnership is…

Read MoreUnlearn and Trace Neuroscience Collaborate to Enhance ALS Clinical Trials
ENHERTU

ENHERTU Phase 3 DESTINY-Gastric05 Trial Starts for Untreated HER2+ Advanced Gastric Cancer

ENHERTU Phase 3 DESTINY-Gastric05 Trial Starts for Untreated HER2+ Advanced Gastric Cancer The first patient has been successfully dosed in the DESTINY-Gastric05 phase 3 trial, which aims to evaluate the efficacy and safety of ENHERTU® (trastuzumab deruxtecan) in combination with…

Read MoreENHERTU Phase 3 DESTINY-Gastric05 Trial Starts for Untreated HER2+ Advanced Gastric Cancer
RNA

Lilly’s RNA Silencer Achieves Nearly 94% Reduction in Key Cardiovascular Biomarker

Lilly’s RNA Silencer Achieves Nearly 94% Reduction in Key Cardiovascular Biomarker Eli Lilly has made a groundbreaking advancement in cardiovascular medicine with its investigational small interfering RNA (siRNA) therapeutic, lepodisiran, which demonstrated a remarkable ability to reduce lipoprotein(a) [Lp(a)] levels…

Read MoreLilly’s RNA Silencer Achieves Nearly 94% Reduction in Key Cardiovascular Biomarker
Novotech ,Clinical Trials

Novotech Report Highlights Surge in siRNA Research with 150+ Clinical Trials (2020-2024)

Novotech Report Highlights Surge in siRNA Research with 150+ Clinical Trials (2020-2024) Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its latest preclinical report exploring the rapidly evolving landscape of small interfering RNA…

Read MoreNovotech Report Highlights Surge in siRNA Research with 150+ Clinical Trials (2020-2024)
COVID-19

Preclinical Intranasal COVID-19 Vaccine Shows Lasting Immunity & Broad Protection

Blue Lake Biotechnology’s Intranasal COVID-19 Vaccine Candidate Demonstrates Long-Lasting Immunity and Broad Protection Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company specializing in intranasal vaccine development, along with its affiliate CyanVac LLC, recently published two pivotal preclinical studies in the…

Read MorePreclinical Intranasal COVID-19 Vaccine Shows Lasting Immunity & Broad Protection
Antiviral

SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 Post-Exposure

SCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 Post-Exposure Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) presented late-breaking scientific findings at the Conference of Retroviruses and Opportunistic Infections (CROI)…

Read MoreSCORPIO-PEP Phase 3: Ensitrelvir First Oral Antiviral to Prevent COVID-19 Post-Exposure